Ramdev, Balkrishna Acharya Ready For ‘Public Apology’; Supreme Court Next Hearing On April 23

New Delhi: The Supreme Court on Tuesday granted a week to Yoga guru Ramdev and Patanjali Ayurved Ltd MD Balkrishna Acharya to take steps to redeem themselves of the alleged contempt after their lawyers offered to issue a public apology for misleading advertisements.

“I am willing to give a public apology,” senior advocate Mukul Rohatgi, appearing for Ramdev and Balkrishna, told a bench of Justices Hima Kohli and Ahsanuddin Amanullah, news agency PTI reported.

The Supreme Court court asked Ramdev and Balkrishna, both of whom were present in the court, to come forward for an interaction with the bench.

“They should feel they have a connect with the court,” the bench said.

The hearing in the matter is underway and the bench is currently interacting with Ramdev.

Ramdev and Balkrishna have tendered an “unconditional and unqualified apology” before the apex court over advertisements issued by the firm making tall claims about the medicinal efficacy of its products.

In two separate affidavits filed in the court, Ramdev and Balkrishna have tendered an unqualified apology for the “breach of the statement” recorded in the November 21 last year order of the apex court.

In the November 21, 2023 order, the top court had noted that counsel representing Patanjali Ayurved had assured it that “henceforth there shall not be any violation of any law(s), especially relating to advertising or branding of products manufactured and marketed by it and, further, that no casual statements claiming medicinal efficacy or against any system of medicine will be released to the media in any form”.

The top court had said Patanjali Ayurved Ltd is “bound down to such assurance”.

The non-observance of the specific assurance and the subsequent media statements irked the apex court, which later issued a notice to them to explain why contempt proceedings be not initiated against them.

Related Posts

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

The report emphasizes that absolute R&D spending remains modest and identifies expanding investment in advanced biologics and AI-driven drug discovery as the “largest opportunity” for bridging the innovation divide. Recent…

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Early-stage activity drove the month, accounting for 73.6 per cent of total investments, while seed-stage rounds contributed the remaining 26.4 per cent. India’s pharma and healthcare funding for November 2025…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Novo Nordisk gears up for December Ozempic launch

Novo Nordisk gears up for December Ozempic launch

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit